CEA Blood Test: What an Elevated Result Means

A high CEA result does not automatically mean cancer, and a low result does not rule it out. This blood test is most useful when a known cancer produces CEA: it can help the care team assess treatment and follow-up. It is not a general cancer screening test for people without symptoms. The reason for testing, changes over time, and other findings give the number its meaning. MedlinePlus on the CEA test

What the CEA test measures

CEA stands for carcinoembryonic antigen. It is a glycoprotein, a protein with sugar chains attached. The body produces more of it during development before birth; healthy adults usually have only small amounts in their blood. CEA belongs to the CEACAM family of molecules, which participate in cell adhesion and signaling. Review of the CEACAM family

Some tumors produce more CEA, particularly certain colorectal cancers. Levels can also rise in lung, breast, pancreatic, or stomach cancer. But CEA is not exclusive to cancer cells. Inflammation and other noncancerous conditions can also accompany higher concentrations. Clinical review

The role of CEACAM molecules in cell interactions and immune processes is biologically interesting. It does not make a blood CEA result a general measure of “cellular health,” repair capacity, or immune surveillance. The test cannot tell you where a change is occurring or what is causing it. Researchers are also investigating the CEACAM family’s role in inflammatory bowel disease. CEACAM and intestinal inflammation

Reference ranges: normal is not the same as optimal

Commonly quoted upper limits are around 3.0 ng/mL for nonsmokers and 5.0 ng/mL for smokers. Mayo Clinic Laboratories, for example, gives a nonsmoker reference limit of 3.0 ng/mL and notes that some smokers have elevations, usually below 5.0 ng/mL. Other laboratories may use different cutoffs. These numbers are guides: the reference range for the actual assay matters more than an internet target. Mayo laboratory reference information Study of age and smoking

A baseline can be useful when there is a medical reason to monitor CEA. A rise from 0.5 to 2.8 ng/mL, for instance, is a measurable change, but it is not proof of disease. Measurement variation, the time between tests, other illnesses, and the tumor’s previous behavior affect its significance. An individual’s trend does not replace clinical context any more than a laboratory cutoff does.

Average concentrations can rise somewhat with age. That does not diagnose tissue damage in an individual. Nor is there an established “optimal” CEA level that healthy people should try to drive ever lower through repeated testing. A persistently elevated result deserves discussion; a result within the reference range cannot reliably exclude cancer.

What a high CEA level can mean

CEA-producing tumors can cause substantial elevations, sometimes many times the laboratory limit. Figures such as 10 to 100 times the limit describe possible magnitudes, not the typical level in every colorectal cancer. Some advanced tumors produce little CEA, while some benign conditions cause abnormal results. The number alone cannot establish a tumor’s type or stage. Review of clinical use

Possible noncancerous associations include inflammatory bowel disease, cirrhosis, pancreatitis, and certain lung conditions such as COPD. In a study of benign lung disease, elevations were mostly modest; values above 20 ng/mL were rare. That finding applies to a particular patient population. It does not establish a threshold below which cancer is ruled out. Study of benign lung disease

Smoking can increase CEA. A result in the range of 3 to 8 ng/mL in someone who smokes is therefore not, by itself, a cancer diagnosis. However, that range is not a normal range for smokers, either. An abnormal result should not simply be attributed to smoking, especially if it continues to rise or symptoms develop.

Neither a threshold of 10 ng/mL nor the range of 3 to 10 ng/mL reliably separates benign from malignant causes. Higher or repeatedly rising values may increase the need for investigation. The most useful threshold also depends on why the test was ordered. Research on colorectal cancer follow-up specifically examines how many recurrences different thresholds detect and how many false alarms they generate. Systematic review of CEA thresholds

What a low CEA level means

Many healthy nonsmokers have low results, for example around 1 to 2 ng/mL. A very low result is generally not a reason for treatment in its own right. But it does not prove that inflammation is low or that cells are repairing themselves particularly well. “Lower means healthier” is too simple a rule for this marker.

With a known CEA-producing tumor, a decline during treatment can be encouraging. Whether treatment is working is assessed alongside symptoms, examination, and imaging when appropriate. The aim of cancer treatment is to control the disease, not merely to achieve the lowest possible laboratory number. Recommendations on gastrointestinal tumor markers

Some tumors release little CEA. The marker may then remain low despite disease and be less useful for monitoring. Differences within the CEACAM family offer avenues for biological research, but a low blood result cannot identify a particular genetic trait. Other investigations are selected according to the specific cancer or clinical question.

What happens during testing

Blood is usually drawn from a vein in the arm. The laboratory uses an antibody-based assay to measure the CEA concentration. Fasting is generally unnecessary for CEA alone. If other tests are being performed at the same time, different preparation instructions may apply. Results may be available within 24 to 48 hours, although the actual turnaround depends on the laboratory.

A single mildly elevated result may prompt a repeat measurement. An interval of 2 to 4 weeks may fit some situations, but it is not a general recommendation to wait. With a pronounced rise, concerning symptoms, or known cancer, the treating team decides whether further investigations are needed immediately.

Testing frequency depends on the cancer, the treatment phase, and the follow-up plan. Commonly mentioned intervals of 3 to 6 or 6 to 12 months cannot be assigned uniformly to active treatment and every follow-up situation. Testing may be more frequent during treatment; after treatment, some plans also call for measurements every 3 to 6 months. MedlinePlus on monitoring

For comparisons, using the same laboratory and method where possible is helpful. New infections, inflammatory conditions, medications, and changes in smoking belong in the discussion of the result. They provide context for a change without automatically explaining it.

What can change a CEA result

Smoking is an important influence. Elevated levels may fall over weeks to months after quitting. In a 1976 study, elevated CEA in participants who stopped smoking fell into the nonsmoker range within three months. That observation is not a guaranteed deadline for every person. If the result remains abnormal, its cause still needs to be considered in context. Study of smoking and CEA

Infections and inflammatory lung conditions can accompany temporary elevations. Researchers have also examined associations in Crohn’s disease, ulcerative colitis, and some rheumatic diseases. This does not make CEA the appropriate standard marker for those conditions. For inflammatory bowel disease activity, other findings and markers, such as fecal calprotectin, are more useful. CEA in bowel inflammation and rheumatic diseases

Temporary changes can occur during cancer treatment. An early increase needs careful interpretation and should not lead someone to stop treatment on their own. Conversely, taking an anti-inflammatory medication does not predict a particular reduction in CEA. Providing the care team with a complete medication list helps with interpretation.

How CEA fits with other laboratory results

Additional tests help when they answer a specific question. CA 19-9 is used in certain pancreatic cancer settings, for example, and CA 125 in some ovarian cancer settings. An indiscriminate panel of tumor markers is not a reliable general cancer screening strategy. Even several elevated markers can have benign causes. Review of ovarian cancer biomarkers

CRP and the erythrocyte sedimentation rate can provide evidence of inflammation. They cannot reliably determine whether elevated CEA comes from cancer or benign inflammation: cancer can also alter inflammatory markers. Studies combining blood measurements test diagnostic models in defined populations; they do not automatically establish a universal testing algorithm. Study of combined blood markers

The liver plays a role in processing CEA, so ALT, AST, and bilirubin may provide additional context. Normal liver results do not exclude liver disease or another relevant cause. An experimental study of a CEA receptor on Kupffer cells describes a possible biological mechanism, rather than clinical proof of a particular diagnostic rule. Receptor-mechanism study

A complete blood count can also matter. Depending on the situation, white blood cells, hemoglobin, and platelets may offer clues about infection, blood loss, or other changes. For example, researchers have studied high platelet counts as a prognostic factor in people undergoing colorectal cancer surgery who also had liver metastases. That finding is not a general explanation for an abnormal CEA result. Study of thrombocytosis Newer combined biomarker models must likewise be assessed for the population in which they are intended to be used. Diagnostic-model study

When a CEA test is most useful

CEA’s main role is in the care of certain cancers that have already been diagnosed. A result before treatment can show whether the tumor produces a measurable amount of the marker. Later results can help identify changes and guide further investigation.

During follow-up, CEA may rise before symptoms or imaging reveal a recurrence. That does not mean every early laboratory signal improves survival, or that stable values justify longer gaps between follow-up visits. In the FACS randomized trial after colorectal cancer treatment, scheduled CEA or CT follow-up increased the proportion of patients undergoing treatment for recurrence with curative intent compared with minimal follow-up. A survival advantage was not established. The distinction matters: finding a treatable recurrence and demonstrating longer survival are different outcomes. FACS trial

During treatment, a downward trend can support an assessment that the cancer is responding. An upward trend may prompt reassessment. Decisions about continuing or changing treatment still depend on the complete clinical picture.

In inflammatory bowel disease, the link between CEA and inflammation is an interesting observation, but it is not a reason to replace established activity markers with CEA. For someone without a known cancer, obtaining a precautionary personal CEA baseline is not an established way to assess cancer risk reliably. A more useful question is which investigation fits the person’s symptoms, history, and recommended cancer screening.

Frequently asked questions

What is a normal CEA level?

Commonly quoted limits are around 3.0 ng/mL for nonsmokers and 5.0 ng/mL for smokers. Laboratories and methods differ; Mayo, for example, uses a nonsmoker limit of 3.0 ng/mL and notes that elevations in smokers are usually below 5.0 ng/mL. Use the range on the actual laboratory report. A normal result does not rule out cancer.

Can a high CEA result mean something other than cancer?

Yes. Smoking, liver disease, inflammatory bowel disease, and certain lung conditions can raise CEA. The level, its trend, and other findings determine which investigations make sense.

How often should CEA be measured?

That depends on the medical reason for testing. With a known cancer, measurements follow the treatment or surveillance plan. Intervals of 3 to 6 months are common in some settings, with shorter or longer intervals in others. Without an appropriate indication, CEA is not a routine screening test.

Does smoking affect the CEA test?

Yes. Smoking can raise the result, and levels may fall over weeks to months after quitting. One study observed a return to the nonsmoker range within three months, but there is no guaranteed deadline. A persistently abnormal result should not be attributed to smoking alone.

What should I do about a high result?

Discuss it with the clinician who ordered the test. Previous results, smoking history, symptoms, and known conditions help with interpretation. Repeating the test after 2 to 4 weeks may fit some circumstances; when concern is greater, further investigations may be needed sooner.

Which other tumor markers are used with CEA?

Depending on the condition, CA 19-9 or CA 125 may have a role. The selection follows the specific clinical question. More markers do not automatically mean greater certainty, and CRP or the erythrocyte sedimentation rate cannot reliably separate cancer from benign causes.

Can inflammation cause elevated CEA?

Yes. Associations have been reported in bowel inflammation and benign lung disease, among other conditions. Elevations are often modest, but a number such as 20 ng/mL is not a reliable boundary for a benign cause. The trend needs to be interpreted in its clinical context.

Sources

• Beauchemin N, Arabzadeh A (2013). Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis. Cancer metastasis reviews, 32(3-4), 643-71. https://doi.org/10.1007/s10555-013-9444-6 Source

• Alexander JC, Silverman NA, Chretien PB (1976). Effect of age and cigarette smoking on carcinoembryonic antigen levels. JAMA, 235(18), 1975-9. https://pubmed.ncbi.nlm.nih.gov/56468/ Source

• Yang Y, Xu M, Huang H, Jiang X, Gong K, Liu Y, Kuang X, Yang X (2021). Serum carcinoembryonic antigen elevation in benign lung diseases. Scientific reports, 11(1), 19044. https://doi.org/10.1038/s41598-021-98513-8 Source

• Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC, ASCO (2006). ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24(33), 5313-27. https://doi.org/10.1200/JCO.2006.08.2644 Source

• Shinkins B, Nicholson BD, James T, Pathiraja I, Pugh S, Perera R, Primrose J, Mant D (2017). What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow-up? A systematic review and secondary analysis of a randomised controlled trial. Health technology assessment (Winchester, England), 21(22), 1-60. https://doi.org/10.3310/hta21220 Source

• Yang S, Wang Y, Li J, Xu K (2026). Diagnostic performance of multimodal biomarkers in colorectal cancer. Scientific reports, 16(1), 6273. https://doi.org/10.1038/s41598-026-37280-w Source

• Niedzielska J, Jastrzębski T (2025). Carcinoembryonic Antigen (CEA): Origin, Role in Oncology, and Concentrations in Serum and Peritoneal Fluid. Journal of clinical medicine, 14(9). https://doi.org/10.3390/jcm14093189 Source

• Kelleher M, Singh R, O’Driscoll CM, Melgar S (2019). Carcinoembryonic antigen (CEACAM) family members and Inflammatory Bowel Disease. Cytokine & growth factor reviews, 47, 21-31. https://doi.org/10.1016/j.cytogfr.2019.05.008 Source

• Rule AH, Goleski-Reilly C, Sachar DB, Vandevoorde J, Janowitz HD (1973). Circulating carcinoembryonic antigen (CEA): relationship to clinical status of patients with inflammatory bowel disease. Gut, 14(11), 880-4. https://doi.org/10.1136/gut.14.11.880 Source

• Hall C, Clarke L, Pal A, Buchwald P, Eglinton T, Wakeman C, Frizelle F (2019). A Review of the Role of Carcinoembryonic Antigen in Clinical Practice. Annals of coloproctology, 35(6), 294-305. https://doi.org/10.3393/ac.2019.11.13 Source

• Polat E, Duman U, Duman M, Derya Peker K, Akyuz C, Fatih Yasar N, Uzun O, Akbulut S, Birol Bostanci E, Yol S (2014). Preoperative serum tumor marker levels in gastric cancer. Pakistan journal of medical sciences, 30(1), 145-9. https://doi.org/10.12669/pjms.301.3968 Source

• Unger A, Panayi GS, Lessof MH (1975). Carcinoembryonic antigen in rheumatic diseases. Rheumatology and rehabilitation, 14(1), 19-24. https://doi.org/10.1093/rheumatology/14.1.19 Source

• Zhang R, Siu MKY, Ngan HYS, Chan KKL (2022). Molecular Biomarkers for the Early Detection of Ovarian Cancer. International journal of molecular sciences, 23(19). https://doi.org/10.3390/ijms231912041 Source

• Zhang X, Wu YY, Qin YY, Lin FQ (2024). The combined detection of hematological indicators is used for the differential diagnosis of colorectal cancer and benign-colorectal lesions. Cancer biomarkers : section A of Disease markers, 39(3), 223-230. https://doi.org/10.3233/CBM-230157 Source

• Bajenova O, Stolper E, Gapon S, Sundina N, Zimmer R, Thomas P (2003). Surface expression of heterogeneous nuclear RNA binding protein M4 on Kupffer cell relates to its function as a carcinoembryonic antigen receptor. Experimental cell research, 291(1), 228-41. https://doi.org/10.1016/s0014-4827(03)00373-2 Source

• Pedrazzani C, Turri G, Mantovani G, Conti C, Ziello R, Conci S, Campagnaro T, Ruzzenente A, Guglielmi A (2019). Prognostic value of thrombocytosis in patients undergoing surgery for colorectal cancer with synchronous liver metastases. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 21(12), 1644-1653. https://doi.org/10.1007/s12094-019-02093-z Source

• Primrose JN, Perera R, Gray A, Rose P, Fuller A, Corkhill A, George S, Mant D, FACS Trial Investigators (2014). Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA, 311(3), 263-70. https://doi.org/10.1001/jama.2013.285718 Source

• Mayo Clinic Laboratories. Carcinoembryonic Antigen (CEA), Serum. https://www.mayocliniclabs.com/test-catalog/Overview/8521